China Meheco Group News

China Pharmaceutical (600056) 2020 Third Quarter Report Review: Q3 performance is in line with expectations, the integrated two-wing strategy is progressing steadily

中信證券Nov 5, 2020 00:00

China Pharmaceutical (600056) 2020 Interim Report Review: International trade has increased dramatically, and industry and commerce have basically recovered

華創證券Sep 1, 2020 00:00

China Pharmaceutical (600056) 2020 China News Review: steady performance growth is in line with expectations and the two-wing strategy continues to advance.

中信證券Sep 1, 2020 00:00

China Pharmaceutical (600056) 2020 Semi-Annual Report Review: Hospital Channels Are Waiting to Resume, Multiple New Varieties Approved

東莞證券Aug 26, 2020 00:00

China Pharmaceutical (600056): the performance improvement is expected under the pressure of the second and third terminals of the industrial plate.

中信證券Apr 28, 2020 00:00

Comments on major issues of China Pharmaceutical (600056): 2.2 billion heavy acquisition of industrial, commercial and trade integrated assets the investment income is expected to increase by 142 million yuan in 2020.

華創證券Nov 11, 2019 00:00

China Pharmaceutical (600056) 2019 Interim Report Review - Performance pressure is basically in line with expectations, the integrated two-wing strategy continues to advance

中信證券Sep 3, 2019 00:00

China Pharmaceutical (600056) Research Report: Actively Responding to Industry Challenges and Continuing to Promote Business Integration

招商證券Aug 31, 2019 00:00

Chinese Medicine (600056): Commerce, international trade pick up, industry meets challenges

中泰證券Apr 29, 2019 00:00

Comments on China Pharmaceutical (600056) 2018 Annual report: the performance of marketing system transformation is lower than expected

中信證券Mar 29, 2019 00:00

中国医药(600056)季报点评：收入增速有所回升 继续推进商业网络布局

上海證券Nov 1, 2018 00:00

中国医药(600056)季报点评：业绩表现平稳 三大业务板块稳定增长

興業證券Oct 30, 2018 00:00

中国医药(600056)三季报点评：收入端开始提速 业绩符合预期

中信證券Oct 30, 2018 00:00

中国医药(600056)季报点评：营收增长加速 工业板块承压

華泰證券Oct 29, 2018 00:00

中国医药(600056)季报点评：工业尚在营销整合阵痛期 商业走出底部

中泰證券Oct 29, 2018 00:00

中国医药(600056)半年报点评：工、商、贸业务盈利能力提升

國聯證券Sep 1, 2018 00:00

中国医药(600056)中报点评：工业板块持续发力 商业板块推进区域扩张

上海證券Aug 31, 2018 00:00

中国医药(600056)中报点评：盈利能力提升 业绩符合预期

中信證券Aug 30, 2018 00:00

中国医药(600056)半年报点评：收入端增速放缓 业务与产品结构优化带动利润增长

天風證券Aug 29, 2018 00:00

中国医药(600056)中报点评：业绩完全符合我们预期 二季度恢复较快增长

招商證券Aug 29, 2018 00:00